<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04481412</url>
  </required_header>
  <id_info>
    <org_study_id>Cetirizine in alopecia</org_study_id>
    <nct_id>NCT04481412</nct_id>
  </id_info>
  <brief_title>Topical Cetirizine in Androgenetic Alopecia in Females</brief_title>
  <official_title>The Role of Cetirizine in Androgenetic Alopecia in Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cetirizine is a safe and selective, second-generation histamine H1 receptor antagonist,
      widely used in daily practice. A study showed that cetirizine causes a significant reduction
      in both the inflammatory cell infiltrate and PGD2 production. A pilot study on topical
      cetirizine showed that cetirizine increased total hair density, terminal hair density and
      diameter. Also, its lower potential side effects if compared with other drugs commonly used
      for AGA, as minoxidil, can promote a wider use and better compliance of cetirizine in the
      future for the treatment of AGA. Combinations of therapies are likely to be more efficacious
      than single treatments.

      Treatments to clinically improve scalp hair density and reduce mid-pattern thinning leading
      to improved scalp coverage are highly important for the affected women. On the basis of the
      above evidence and lacking studies that confirm the effectiveness of cetirizine in AGA
      treatment, the aim of this study is to evaluate the efficacy and tolerability of topical
      cetirizine in female patients with AGA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Androgenetic alopecia (AGA) is the most common form of alopecia in men and women. It is a
      hereditary, androgen-dependent, progressive thinning of scalp hair that follows a defined
      pattern. The disease mechanism is still relatively poorly understood, but involves a strong
      genetic contribution as well as some environmental input. AGA manifests as a noticeable
      reduction of scalp hair coverage, shorter miniaturized telogen vellus hair follicles, and
      significantly slower rates of hair growth. Approximately 6% to 38% of healthy women
      experience some degree of frontal and frontoparietal hair loss. AGA may have significant
      impact on quality of life in female patients. When female AGA is associated with high levels
      of androgens, systemic antiandrogenic therapy may be needed. However, treating it with oral
      antiandrogens is usually ineffective suggesting that most female AGA cases are not systemic
      androgen dependent and topical treatment may be more appropriate.

      Currently, the only clinically validated and licensed medication approved for increasing hair
      density in women with AGA is 2 % minoxidil topical solution, and up to 5% minoxidil in
      several countries. The collective effects of minoxidil lead to increased cutaneous blood
      flow, prolongation of the anagen growth phase, and increase in the size of smaller hair
      follicles. However, it produces moderate results, and must continue to be used to have a
      continued benefit, and may produce adverse side effects. The use of higher concentrations of
      minoxidil in women is supported by results from an early study suggesting that concentrations
      higher than 2% could improve efficacy without increasing the rates of adverse events when
      applying not more than 60 mg of minoxidil per day.

      Based on the hypertrichosis observed in patients treated with analogues of prostaglandin F2a
      (PGF2a) (i.e. latanoprost used for glaucoma), it was supposed that prostaglandins would have
      an important role in hair growth. Their action is variable depending on the class they belong
      to: prostaglandin E(PGE) and PGF2a play a generally positive role on the hair growth, while
      PGD2 has an inhibitory role on the hair growth. Elevated levels of prostaglandin D2 synthase
      (PGDS) were found at the messenger ribonucleic acid (mRNA) and protein levels in bald scalp
      versus haired scalp of men with AGA; as well as the enzymatic product of PGDS, (PGD2), is
      generally elevated in bald human scalp tissue.

      Cetirizine is a safe and selective, second-generation histamine H1 receptor antagonist,
      widely used in daily practice. A study showed that cetirizine causes a significant reduction
      in both the inflammatory cell infiltrate and PGD2 production. However, these effects
      apparently are not related to its anti-H1 activity. A pilot study on topical cetirizine
      showed that cetirizine increased total hair density, terminal hair density and diameter.
      Also, its lower potential side effects if compared with other drugs commonly used for AGA, as
      minoxidil (which often cause of hypertrichosis, contact allergic dermatitis, headache and
      hypotension), can promote a wider use and better compliance of cetirizine in the future for
      the treatment of AGA. Combinations of therapies are likely to be more efficacious than single
      treatments.

      Treatments to clinically improve scalp hair density and reduce mid-pattern thinning leading
      to improved scalp coverage are highly important for the affected women. On the basis of the
      above evidence and lacking studies that confirm the effectiveness of cetirizine in AGA
      treatment, the aim of this study is to evaluate the efficacy and tolerability of topical
      cetirizine in female patients with AGA.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 16, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change from baseline in number of terminal hairs, growing hair and vellus hair</measure>
    <time_frame>baseline, 12, 24 weeks</time_frame>
    <description>Trichoscopic evaluation: of frontal, occipital and temporal areas regarding the change from baseline in number of terminal hairs, growing hair and vellus hair.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in hair shaft thickness</measure>
    <time_frame>baseline, 12, 24 weeks</time_frame>
    <description>Trichoscopic evaluation: of frontal, occipital and temporal areas regarding the change from baseline in hair shaft thickness.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in number of follicular openings</measure>
    <time_frame>baseline, 12, 24 weeks</time_frame>
    <description>Trichoscopic evaluation: of frontal, occipital and temporal areas regarding the change from baseline in number of follicular openings.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change from baseline in number of hairs erupting from each follicle</measure>
    <time_frame>baseline, 12, 24 weeks</time_frame>
    <description>Trichoscopic evaluation: of frontal, occipital and temporal areas regarding the change from baseline in number of hairs erupting from each follicle.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in patient self-assessment from baseline</measure>
    <time_frame>baseline, 6, 12, 18, 24 weeks</time_frame>
    <description>Patient self-assessment of hair growth will be determined by means of a set of predetermined 5 questions in Arabic, each of which asks the patient about a specific aspect of their hair compared with the start of the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in hair growth from baseline using global photographic assessment</measure>
    <time_frame>baseline, 6, 12, 18, 24 weeks</time_frame>
    <description>Standardized photographs of the scalp will be taken.
An expert panel of 3 blinded dermatologists will evaluate hair growth or loss from baseline by comparing baseline with follow-up photographs of each subject by means of a 7-point scale to answer the following question: &quot;How would you subjectively rate the patient's hair growth at this time point compared to baseline?&quot;. The scale ranges from-3 ( greatly decreased) to +3 (greatly increased). Assessments will be made at the 12th and 24th week by comparing the global photographs taken at baseline with those taken at each visit.
Investigator assessment: Same as the expert panel assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse effects</measure>
    <time_frame>6, 12, 18, 24 weeks</time_frame>
    <description>Reports of adverse effects or local intolerance, if any, will be collected at every visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Androgenetic Alopecia</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(30) patients will apply topical minoxidil (5%) once daily and topical cetirizine (1%) once daily on their scalp for 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(30) patients will apply topical minoxidil (5%) once daily and placebo once daily on their scalp for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical cetirizine</intervention_name>
    <description>Topical cetirizine 1% spray that will be prepared at Faculty of Pharmacy, Cairo University and will be applied once daily.</description>
    <arm_group_label>Study group</arm_group_label>
    <other_name>Cetirizine 1%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>96% ethanol that will be applied once daily.</description>
    <arm_group_label>Control group</arm_group_label>
    <other_name>96% ethanol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical minoxidil</intervention_name>
    <description>Topical Minoxidil 5% that will be applied once daily.</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Study group</arm_group_label>
    <other_name>Minoxidil 5%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females with androgenetic alopecia of age 20-50 years.

          2. Patients experiencing active hair loss within the last 12 months.

          3. Sinclair scale 2 and 3.

          4. Patients willing to continue their current regimen of vitamins and nutritional
             supplements and not start any new vitamins or nutritional supplements for the duration
             of the study.

          5. Patients willing to use a mild non-medicated shampoo and conditioner for the duration
             of the study.

          6. Patients who did not receive topical or systemic treatment for androgenetic alopecia
             or prostaglandins in the last 6 months.

        Exclusion Criteria:

          -  1. Patients with a chronic dermatological condition (eczema, psoriasis, infection,
             etc) of the scalp other than FPHL.

             2. Subjects who had hair transplants, scalp reduction, current hair weave or tattooing
             in the target area, which makes it difficult to perform hair count assessment.

             3. Subjects who received radiation therapy to the scalp, or has had chemotherapy in
             the past year.

             4. Subjects who have a known underlying medical problem that could influence hair
             growth such as HIV infection, connective tissue disease, a thyroid condition,
             inflammatory bowel disease or other medical conditions, at the discretion of the
             investigator.

             5. Subjects with clinical diagnosis of alopecia areata or other non-AGA forms of
             alopecia.

             6. Pregnant or lactating females or planning to become pregnant for the duration of
             the study.

             7. Patients with severe cardiovascular disease, uncontrolled or untreated
             hypertension, arrythmia or clinically relevant hypotension.

             8. Subjects with hair loss for greater than 5 years, as medical therapy is unlikely to
             have much effect at restoring hair follicles inactive for that long of a period.

             9. The subject has known hypersensitivity or previous allergic reaction to any of the
             active or inactive components of the test articles.

             10. Patients using any medications that potentially cause drug-induced hair loss
             (e.g., depotestosterone, haloperidol, methotrexate, methylprednisolone, prednisone,
             testosterone, divalproex sodium) within the last 3 months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Females with androgenetic alopecia of age 20-50.</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maggie Abbassi, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Pharmacy, Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hanan Nada, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Samar Farid, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Faculty of Pharmacy, Cairo University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eglal Bassiouny, MSc</last_name>
    <phone>00201061500242</phone>
    <email>eglal.mostafa@pharma.cu.edu.eg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Al-Kasr Al-Ainy outpatient dermatology clinic</name>
      <address>
        <city>Cairo</city>
        <state>ŸêAl-Kasr Al-Ainy</state>
        <zip>11559</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanan Nada, PhD</last_name>
      <phone>00201023000226</phone>
      <email>hananrnada@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Jaworsky C, Kligman AM, Murphy GF. Characterization of inflammatory infiltrates in male pattern alopecia: implications for pathogenesis. Br J Dermatol. 1992 Sep;127(3):239-46.</citation>
    <PMID>1390168</PMID>
  </reference>
  <reference>
    <citation>Guo H, Gao WV, Endo H, McElwee KJ. Experimental and early investigational drugs for androgenetic alopecia. Expert Opin Investig Drugs. 2017 Aug;26(8):917-932. doi: 10.1080/13543784.2017.1353598. Epub 2017 Jul 12. Review.</citation>
    <PMID>28689433</PMID>
  </reference>
  <reference>
    <citation>Rossi A, Campo D, Fortuna MC, Garelli V, Pranteda G, De Vita G, Sorriso-Valvo L, Di Nunno D, Carlesimo M. A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia. J Dermatolog Treat. 2018 Mar;29(2):149-151. doi: 10.1080/09546634.2017.1341610. Epub 2017 Jun 29.</citation>
    <PMID>28604133</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2020</study_first_posted>
  <last_update_submitted>July 17, 2020</last_update_submitted>
  <last_update_submitted_qc>July 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Samar Farghali Farid</investigator_full_name>
    <investigator_title>Head and professor of clinical pharmacy department</investigator_title>
  </responsible_party>
  <keyword>cetirizine</keyword>
  <keyword>minoxidil</keyword>
  <keyword>androgenetic alopecia (AGA)</keyword>
  <keyword>Female pattern hair loss (FPHL)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alopecia</mesh_term>
    <mesh_term>Alopecia Areata</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetirizine</mesh_term>
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Minoxidil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

